Market Cap 561.54M
Revenue (ttm) 15.93M
Net Income (ttm) -199.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,251.35%
Debt to Equity Ratio -6.42
Volume 169,100
Avg Vol 94,714
Day's Range N/A - N/A
Shares Out 95.66M
Stochastic %K 85%
Beta 0.66
Analysts Strong Sell
Price Target $15.88

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 80 44 75 00
Address:
50 rue de Dijon, Daix, France
BioRich
BioRich Oct. 25 at 10:32 PM
$ALT Remember this? This was my first time trying I tried to help ALTers realize they were in the wrong liver (MASH/Fibrosis) play. Since this, $ALT is down 41% and $IVA is up 103%. If you're still holding $ALT after all of the warnings, don't be mad at me or other truth sharers. This one is on you.
0 · Reply
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
Jonita
Jonita Oct. 24 at 4:41 PM
$IVA ready to 💣💣💣
0 · Reply
BioRich
BioRich Oct. 23 at 9:08 PM
$ALT Continues to add positions to GIA, and $IVA continues to march for with their excellent Fibrosis/MASH P3 trials. The French Connection was strong today. Does anyone have access to any of the readout/SWOT analysis that was done today? Would love to see it and dissect it. Cheers!
0 · Reply
BioRich
BioRich Oct. 23 at 4:12 PM
$ALT $IVA Looks like $IVA's French Connection is benefitting them today at MOSAIC. Oh to be a fly on the wall. Cheers!
0 · Reply
BioRich
BioRich Oct. 23 at 12:31 AM
$ALT, how do you feel about $IVA having the REAL French Connection tomorrow? $IVA, a French company, will be debating $ALT at the French Embassy seems like a pretty solid French Connection. Oh, and for good measure, $IVA has better data, is further along in trials and likely the focus of much M&A activity. All things $ALT wishes they could have. Cheers!
2 · Reply
BioRich
BioRich Oct. 22 at 8:58 PM
$ALT Gonna be fun watching Dr. Harris get destroyed by $IVA tomorrow. Not only did they choose someone else for the CMO position Dr. Harris was rumored to be interested in, but they've got a better product that's further along. I wish this massacre was televised. Cheers!
2 · Reply
BiggustDickus
BiggustDickus Oct. 22 at 2:55 PM
$IVA Blue Horseshoe loves Inventiva.
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 22 at 1:47 PM
$IVA just reversed 12% higher to -3% (~21Kv) in the last few minutes, follow for more volatility.
0 · Reply
Quantumup
Quantumup Oct. 21 at 8:31 PM
Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.
0 · Reply
Latest News on IVA
Inventiva Announces the Implementation of a New ATM Program

Oct 14, 2025, 4:00 PM EDT - 11 days ago

Inventiva Announces the Implementation of a New ATM Program


Inventiva S.A. (IVA) Analyst/Investor Day Transcript

Oct 8, 2025, 7:16 PM EDT - 16 days ago

Inventiva S.A. (IVA) Analyst/Investor Day Transcript


Inventiva to Host Analyst and Investor Event on October 8, 2025

Sep 24, 2025, 4:00 PM EDT - 4 weeks ago

Inventiva to Host Analyst and Investor Event on October 8, 2025


Inventiva receives $10 million milestone payment from CTTQ

Jul 7, 2025, 4:00 PM EDT - 3 months ago

Inventiva receives $10 million milestone payment from CTTQ


Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:30 AM EDT - 5 months ago

Inventiva reports 2025 First Quarter Financial Information¹


Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 10:50 AM EDT - 7 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript


Inventiva reports 2024 Third Quarter Financial Information¹

Nov 21, 2024, 4:00 PM EST - 1 year ago

Inventiva reports 2024 Third Quarter Financial Information¹


BioRich
BioRich Oct. 25 at 10:32 PM
$ALT Remember this? This was my first time trying I tried to help ALTers realize they were in the wrong liver (MASH/Fibrosis) play. Since this, $ALT is down 41% and $IVA is up 103%. If you're still holding $ALT after all of the warnings, don't be mad at me or other truth sharers. This one is on you.
0 · Reply
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
Jonita
Jonita Oct. 24 at 4:41 PM
$IVA ready to 💣💣💣
0 · Reply
BioRich
BioRich Oct. 23 at 9:08 PM
$ALT Continues to add positions to GIA, and $IVA continues to march for with their excellent Fibrosis/MASH P3 trials. The French Connection was strong today. Does anyone have access to any of the readout/SWOT analysis that was done today? Would love to see it and dissect it. Cheers!
0 · Reply
BioRich
BioRich Oct. 23 at 4:12 PM
$ALT $IVA Looks like $IVA's French Connection is benefitting them today at MOSAIC. Oh to be a fly on the wall. Cheers!
0 · Reply
BioRich
BioRich Oct. 23 at 12:31 AM
$ALT, how do you feel about $IVA having the REAL French Connection tomorrow? $IVA, a French company, will be debating $ALT at the French Embassy seems like a pretty solid French Connection. Oh, and for good measure, $IVA has better data, is further along in trials and likely the focus of much M&A activity. All things $ALT wishes they could have. Cheers!
2 · Reply
BioRich
BioRich Oct. 22 at 8:58 PM
$ALT Gonna be fun watching Dr. Harris get destroyed by $IVA tomorrow. Not only did they choose someone else for the CMO position Dr. Harris was rumored to be interested in, but they've got a better product that's further along. I wish this massacre was televised. Cheers!
2 · Reply
BiggustDickus
BiggustDickus Oct. 22 at 2:55 PM
$IVA Blue Horseshoe loves Inventiva.
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 22 at 1:47 PM
$IVA just reversed 12% higher to -3% (~21Kv) in the last few minutes, follow for more volatility.
0 · Reply
Quantumup
Quantumup Oct. 21 at 8:31 PM
Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.
0 · Reply
BioRich
BioRich Oct. 21 at 4:00 PM
$ALT Friendly reminder for the Pumpers: 1) $ALT is "Late Breaking" because of the calendar, not the content. 2) Submission date was May 29th. They hadn't finished "reviewing" data at that point. 3) Data was released June 25/26, which makes the ineligible for normal submission and had to do late breaking. 4) $ALT is presenting the SAME data they already presented in June. This is a nothing burger other than watching them dance about how/why they FAILED Fibrosis. 5) $ALT discussing AI results is lame as well. Others like $IVA are presenting informative examples of AI (and it's values). $ALT will be doing a dance to try to make you think they passed their FAILED Fibrosis Endpoint. 6) Added bonus to $ALT's carrot waving strategies is that they get 1 extra month of retail chatter and pumping because the embargo on Late Breaking ends basically as The Meeting begins. $ALT has been lackluster for every major conference and this is no different. Congrats to those that have listened and exited.
0 · Reply
BioRich
BioRich Oct. 18 at 11:26 PM
$ALT Since ALTers are following my recommendation and looking at $IVA's excellent Fibrosis data, in an oral form, the "negative" I see some mentioning is related to weight gain. Here's a little bit to help (See below). From a perspective standpoint, if someone is dealing with Fibrosis, they're taking the BEST drug for Fibrosis. Weight loss can be achieved in a million different ways so any suggestion to discredit $IVA's exceptional results is embarrassing. Especially coming from a company ($ALT) that has the most questiinable WL data in the sector. Congrats $IVA. Glad to be a heavy shareholder now as we approach what I expect to be a lucrative deal with BP. Cheers!
0 · Reply
BioRich
BioRich Oct. 18 at 5:08 AM
$ALT As a long (shareholder), I find it disturbing that $ALT is sending their outgoing CMO (Dr. Harris) to the MOSAIC debate. Dr. Harris announced his retirement early in $ALT's P2b MASH trial, which ultimately failed hitting their oh so important Fibrosis Endpoint. Dr. Harris has already eagerly said he's looking forward to opportunities outside of ALT to help the sector so representing $ALT seems odd. Seeing as heavy hitters from $IVA will be represented (who successfully showed significant fibrosis improvement, and are already in P3), this could be a blood bath for $ALT. I don't expect this to end well for out beloved $ALT. Follow/Subscribe for more suggestions and perspective. Cheers!
1 · Reply
BioRich
BioRich Oct. 16 at 10:57 PM
$ALT @Wolly99 @Turribull @Designed2Gain Our resident 80%er sharing exciting information about another company's AASLD presentation. Great news for them. I've also highlighted the cT1 focused information from MDGL and others. Take a look at $IVA's AASLD presentations if you want to get super excited about the role of NITs moving forward. Sad to see ALTers pumping other companies/drugs unknowingly while ALT continues to screw them. It doesn't even look like $ALT is invited anymore. That Fibrosis FAILURE continues to haunt them. Well, that and questionable data. Cheers $MDGL, $VKTX, $MTVA for your solid future in MASH/Fibrosis. $ALT, maybe you can hand out free samples of Dose at the door. Cheers!
0 · Reply
BioRich
BioRich Oct. 16 at 4:13 PM
$ALT FAILED Fibrosis. That's what WS wanted. They missed and now they are but a cat toy for WS to play and make money. Longs will make excuses, while seeing red. NITs help everyone. AI helps everyone. Obesity is dead. MASH is dime a dozen. $ALT went for the homren with Fibrosis and they failed. If you want to invest in the sector, invest in $IVA. Their ORAL drug performed 77% better than Placebo. If you want to donate money, toss it towards Garg and Co at $ALT who only performed 25% better than Placebo. These are facts folks, not hopes and casino dreams. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!
0 · Reply
aletz
aletz Oct. 16 at 10:39 AM
$IVA https://www.biostockinfo.com/iva/ My DD on IVA, long read
0 · Reply
Quantumup
Quantumup Oct. 16 at 10:23 AM
Citizens reit'd $MDGL Mkt OP-$485 $IVA LLY $NVO ALGS Citizens JMP said: Our 3Q25 physician survey confirmed the Rezdiffra launch is continuing its strong momentum, with docs prescribing it to more patients, more patients getting on paid drug, discontinuations remaining low, and expected utilization staying high. Competitively, docs said they expect to increase Wegovy usage following its formal approval, and we are interested in tracking this dynamic as Novo's recent acquisition of AKRO's FGF21 analog efruxifermin (in Phase 3) shows the pharma thinks a more potent anti-fibrotic than Wegovy is necessary. We remain confident in our ~$7B U.S. peak sales estimate. For 3Q25, our $240M estimate is slightly below consensus of $244M. For 2025, we model $863M in Rezdiffra sales (vs. consensus of $873M). We expect MDGL to report its 3Q25 financial results in the coming weeks and we look forward to management's commentary on the underlying dynamics, especially increased GTN in 2H25 and patient demand.
0 · Reply
BioRich
BioRich Oct. 15 at 9:33 PM
$ALT For those "hoping" that $ALT addresses Fibrosis, why not just buy the one that shows positive effects on Fibrosis Improvement. For those that are worried about being under in your $ALT bet, just realize if you had taken your 50% loss when $ALT's Failed their trial endpoint and bought $IVA, you would have made your money back, and then some. You would have also been aligned with a P3 asset that will likely get approved, rather than a failed asset that you hope the FDA looks the other way on. Emotional investing is destroying y'all. It's not too late to correct a wrong. And for those "waiting until 48W data" or "EoP2 Meeting", you'll lose more money. I expect a 36% drop on the 48W data, and FDA to hammer $ALT with a huge trial coming out of the EoP2 meeting, which means $ALT will drag you along like they did with their Failed Obesity Program. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. Let's make some money. Cheers! $XBI $MDGL $VKTX
1 · Reply
BioRich
BioRich Oct. 15 at 9:12 PM
$XBI Looks like yesterday's picks turned out pretty well, led by $SBFM. I see that continuing to run as it gets more attention. Could be a multi-bagger. Also, 1) $GUTS My #1 "Must Have" Bio. You thought Wegovy was a big deal, check out his beauty. Retains weight loss when you discontinue a GLP-1 and also has shown insane weight loss in early models using gene therapy (not their lead, but very exciting). Will be subject of massive BO/PS. 2) $IVA If you're interested in the MASH/Fibrosis/Liver space (which is increasingly becoming as popular as Obesity), this is your pick. P3 with impressive Fibrosis Improvement data. Expect them to get BO too. 3) Added more $GDRX. This was a great pick at these levels before the TrumpRX news. Still a great pick and will go parabolic if TrumpRx takes off and uses GDRX (No political posts, please). Follow/Subscribe for more suggestions/perspective. Would love to hear yours too. Let's make some money. Cheers!
1 · Reply
BioRich
BioRich Oct. 15 at 8:52 PM
$ALT Friendly reminder for those looking towards this ticker for the next big thing...RUN! The Bulls on this page spread misinformation and act like Uncle Rico about what could have been. They won't tell you the truth, but this company failed their trial, they have discontinued countless programs, they withhold data (while diluting) and are facing intense legal and securities fraud attention. Simple test...if it did 1/3 of what this board pumps "it does", this would be trading at $20/share. It's not, and for good reason. If you want in the MASH/fibrosis race, get some $IVA. If you want in the Obesity sector, invest as heavily as you possibly can in $GUTS. $VERU is an interesting one and $TERN continues to soar on the cusp on transformational data. Follow/Subscribe for more suggestions and pespective. Would love to hear yours too. That's how we find these gems (not ALT) and learn. Let's make some money. Cheers!
0 · Reply
aletz
aletz Oct. 15 at 8:38 PM
$IVA I added more from French exchange
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 15 at 1:12 PM
$IVA (-7.1% pre) Inventiva (IVA) files $300M mixed shelf https://ooc.bz/l/80625
0 · Reply